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Introduction
The liaison between muscular dystrophy and heart dysfunction is 
well known in medical genetics. More than 90 muscular dystrophy 
phenotypes have been identified, of which the majority also dis-
play cardiac manifestations (1–3). Both dilated cardiomyopathies 
and cardiac arrhythmia phenotypes are often found as comor-
bidities and may even precede the onset of the muscle symptoms 
(4–6). The limb-girdle muscular dystrophies (LGMDs) are inher-
ited diseases with onset after birth and are characterized by pro-
gressive weakness and muscle atrophy predominantly affecting 
the hips, shoulders, and proximal extremity muscles (3). There 
are both autosomal dominant (LGMD1) and autosomal recessive 
(LGMD2) subtypes known. Today, a total of 31 different LGMD 
loci have been identified (7). A variety of mutations are known in 
the corresponding genes, which belong to several different cellu-
lar pathways, including sarcolemmal glycoproteins (dystroglycan 
and sarcoglycans), scaffolding proteins (caveolin-3 [CAV3]), and 
proteins involved in membrane repair and vesicle trafficking (dys-
ferlin [DYSF] and anoctamin-5 [ANO5]) (7).
POPDC1, which is also known as BVES, is a member of the 
Popeye domain–containing (Popdc) gene family, encoding trans-
membrane proteins, which is highly expressed in cardiac and skel-
etal muscle in an overlapping manner (8, 9). POPDC proteins pos-
sess the evolutionarily conserved Popeye domain, which functions 
as a high-affinity cAMP-binding site (8, 10). POPDC proteins are 
localized primarily at the plasma membrane and in t-tubules (10), 
although they have also been found at the nuclear envelope of 
striated muscle cells (11). An interaction of POPDC proteins with 
CAV3 and the 2-pore domain potassium channel TREK-1 has been 
reported (10, 12). In the presence of POPDC proteins, TREK-1 cur-
The Popeye domain–containing 1 (POPDC1) gene encodes a plasma membrane–localized cAMP-binding protein that is 
abundantly expressed in striated muscle. In animal models, POPDC1 is an essential regulator of structure and function 
of cardiac and skeletal muscle; however, POPDC1 mutations have not been associated with human cardiac and muscular 
diseases. Here, we have described a homozygous missense variant (c.602C>T, p.S201F) in POPDC1, identified by whole-
exome sequencing, in a family of 4 with cardiac arrhythmia and limb-girdle muscular dystrophy (LGMD). This allele was 
absent in known databases and segregated with the pathological phenotype in this family. We did not find the allele in a 
further screen of 104 patients with a similar phenotype, suggesting this mutation to be family specific. Compared with WT 
protein, POPDC1S201F displayed a 50% reduction in cAMP affinity, and in skeletal muscle from patients, both POPDC1S201F and 
WT POPDC2 displayed impaired membrane trafficking. Forced expression of POPDC1S201F in a murine cardiac muscle cell line 
(HL-1) increased hyperpolarization and upstroke velocity of the action potential. In zebrafish, expression of the homologous 
mutation (popdc1S191F) caused heart and skeletal muscle phenotypes that resembled those observed in patients. Our study 
therefore identifies POPDC1 as a disease gene causing a very rare autosomal recessive cardiac arrhythmia and LGMD, 
expanding the genetic causes of this heterogeneous group of inherited rare diseases.
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town of about 3,000 inhabitants located in Calabria (Italy) showed 
an interesting pseudodominant inheritance, compatible with con-
sanguinity and geographic isolation (Figure 1A). The grandfather, 
81 years old at the time of writing (PTI-1), started to complain of 
lower limb-girdle weakness around the age of 40 and lost the ability 
to walk without aids around the age 60. At that time, blood creatine 
kinase (CK) was elevated (range, 750–1300 IU/l). At the age of 60, 
a muscle biopsy was performed in his left deltoid muscle showing 
muscular dystrophy changes, with diameter variability, increased 
central nuclei, and the presence of a few necrotic and regenerat-
ing fibers (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI79562DS1). Transmis-
sion electron microscopy (TEM) analysis revealed the presence of 
plasma membrane discontinuities and submembraneous vacuoles 
(Figure 1, B–D). Expression of dystrophin (DYS), all sarcoglycans, 
emerin, merosin, and CAV3 was normal (data not shown). At age 
59, this patient started to complain of repeated syncope episodes, 
and a second-degree AV block was disclosed. A pacemaker was 
placed 1 year later at the age of 60. Echocardiography excluded 
a cardiomyopathy. Muscle testing at the age of 72 showed a clear 
symmetrical weakness of the limbs (neck flexors Medical Research 
Council Scale for Muscle Strength [MRC] 5; ileopsoas MRC 3.5; 
quadriceps MRC 2; glutei MRC 1; gastrocnemius MRC 5; foot 
rents are potentiated due to enhanced membrane trafficking (10). 
The Popdc1 null mutant in mice displays a retardation of muscle 
regeneration (13). Moreover, an impaired recovery from cardiac 
ischemia and an increase in infarct size have been described in 
the Popdc1 null mutant (12). Both Popdc1 and Popdc2 null mutants 
display a stress-induced sinus node bradycardia, which develops 
in an age-dependent manner (10, 14). In zebrafish, popdc2 mor-
phants develop embryonic heart failure, atrioventricular (AV) 
block, and muscular dystrophy (15). Thus, both heart and skeletal 
muscle pathologies have been associated in model organisms with 
the loss of either Popdc1 or Popdc2. However, so far, Popdc genes 
have never been associated with human hereditary diseases.
We report here the identification of a homozygous reces-
sive mutation in POPDC1 (c.602C>T, p.S201F) by whole-exome 
sequencing (WES) in a family with LGMD and AV block. We demon-
strate that POPDC1S201F has strong pathogenic consequences, since 
it affects cAMP binding and subcellular localization of the mutant 
protein and its interaction partners. Therefore POPDC1 is a disease-
causing gene associated with LGMD and cardiac arrhythmia.
Results
POPDC1 is a disease-causing gene associated with cardiac disturbances 
and LGMD. A family originating from a small Albanian enclave 
Figure 1. Identification of the POPDC1S201F mutation associated with AV block and LGMD. (A) Pedigree of a family homozygous for the POPDC1S201F muta-
tion. The index patient (PTIII-2) and his brother (PTIII-1) suffered from AV block and the grandfather (PTI-1) from LGMD and AV block. (B) TEM analysis of 
skeletal muscle of PTI-1 revealed the presence of plasma membrane discontinuities (arrows) and subsarcolemmal and intermyofibrillar vacuoles (aster-
isks). C and D show higher magnifications of the boxed areas in B. Scale bars: 2 μm (B); 1 μm (C and D). Data depicted are representative of results derived 
from a single biopsy. (E) Holter ECG of the index patient (PTIII-2) displaying an episode of a paroxysmal AV block. (F) Electropherogram of the Sanger 
sequencing of genomic DNA isolated from family members. (G) Sequence alignment of part of the Popeye domain demonstrating sequence conservation. 
Many residues are identical (turquoise) or similar (green); however, S201 (yellow) is ultraconserved. (H) 3D model of the Popeye domain. Only the phosphate-
binding cassette (PBC) is shown. Two hydrogen bonds are formed by S201, but these are lost when the F201 (turquoise) mutant residue is present, possibly 
affecting the ligand-binding affinity of the Popeye domain.
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ure 3A). Muscle biopsy was proposed and refused by the patient. 
The younger brother (PTIII-2) started to complain of syncope 
episode with facial trauma at the age of 12 years. At that age, the 
CK level was elevated to 7643 IU/l after prolonged exercise and to 
3182 IU/l at rest. During hospitalization, the ECG was normal and 
Holter monitoring showed occasional episodes of second-degree 
AV block (Mobitz 1) (Supplemental Figure 2, D–F). The head-up 
tilt test showed sinus bradycardia and escape junctional rhythm in 
the absence of symptoms. Echocardiography was normal, exclud-
ing a cardiomyopathy. The endocavitary electrophysiological study 
documented a normal His bundle–ventricle (HV) interval (30 ms) 
and an advanced infranodal AV block during atrial pacing at a cycle 
length of less than 600 ms. For these reasons, a single-chamber 
dorsal flexors MRC 5). The grandfather had 2 healthy sons and 3 
healthy daughters. One of the daughters had 2 children showing 
the same phenotype as the grandfather, although apparently both 
parents denied consanguinity. The eldest son (PTIII-1), 25 at the 
time of this writing, started to manifest syncopal episodes dur-
ing exercise at the age of 17, and his CK level was elevated to 1216 
IU/l. The electrocardiogram at that age showed a second-degree 
AV infra-Hisian block with no aberrant intraventricular conduction 
and negative response to intravenous flecainide. Holter monitoring 
revealed episodes of paroxysmal second-degree AV block (Mobitz 
2) (Figure 1E and Supplemental Figure 2, A–C). Echocardiogra-
phy was normal. An endocardial double-chamber pacemaker was 
implanted. The muscle CT scan was normal (Supplemental Fig-
Figure 2. Membrane trafficking of POPDC1 is affected in muscle biopsies. Skeletal muscle biopsies of PTI-1 and PTIII-1 and 2 controls were immunos-
tained for (A–D) POPDC1 (green signal) and SCGA (red signal). (E) The immunofluorescence signals were quantified in 10 muscle fibers of 3 sections per 
biopsy. The signals of POPDC1 and SGCA and the ratio of both were plotted relative to the means of both controls, which were set at 1. (F–Q) Subcellular 
localization of POPDC1 in (F–H) CT1, (I–K) CT2, (L–N) PTI-1, and (O–Q) PTIII-2. Perinuclear localization of POPDC1 is only weakly present in control samples, 
whereas in patients’ muscle biopsies, a significant perinuclear accumulation of the mutant protein was seen. Scale bars: 10 μm (A–D, G, H, J, K, M, N, P, 
and Q); 20 μm (F, I, L, and O). (R and S) Western blot analysis of (R) POPDC1 expression in skeletal muscle biopsies and of (S) POPDC1 and POPDC2 in der-
mal fibroblasts of 2 controls (CT1 and CT2) and PTI-1 and PTIII-2. The main POPDC1 isoform in R is labeled by POPDC1. Additional isoforms are indicated by 
arrows, while bands, which are considered to be unspecific and remain present after peptide competition (Supplemental Figure 4, A and B), are indicated 
by an asterisk. Results are representative of 3 independent experiments.
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cal phenotype gave a negative result, suggesting this mutation to 
be very rare and family specific (Supplemental Table 1). The S201F 
mutation is located within the Popeye domain, which is the most 
conserved part of POPDC1 and functions as a cAMP-binding 
domain (10). S201 is a residue of the ultraconserved DSPE motif, 
which is thought to be part of the phosphate-binding cassette (Fig-
ure 1G and refs. 9, 10, 14). In a 3D model of the Popeye domain (10), 
S201 is predicted to be localized to the nucleotide-binding region 
facing the cyclic AMP molecule, and its hydroxyl group might 
possibly engage via hydrogen bonding either with the 2′-hydroxyl 
group of the ribose ring or the side chain amine group of K255, 
which is located in the lid helix αC and potentially controls the allo-
steric transfer of cAMP binding (Figure 1H). In the S201F protein 
model, the aromatic side chain of the introduced phenylalanine 
protrudes into the cAMP-binding pocket, thereby likely impairing 
cyclic nucleotide binding and exchange.
The S201F mutation affects membrane trafficking of both POPDC1 
and POPDC2. In healthy skeletal muscle fibers, POPDC1 and 
endocardial (VVI) pacemaker was implanted, which after 8 years 
was upgraded to a double-chamber pacemaker. The muscle biopsy 
was normal (data not shown), and a CT scan at the age of 19 years 
did not show skeletal muscle involvement despite a very high CK 
level (Supplemental Figure 3B). At the time of this writing, the 
patient was being periodically checked and had not shown further 
episodes of syncope or other symptoms.
Using WES, we identified in this family a homozygous mis-
sense mutation (c.602C>T, p.S201F) in POPDC1. The S201F vari-
ant has not been reported in any of the known databases, such as 
dbSNP (16), 1000 Genomes (17), the NHLBI Exome Sequencing 
Project (18), and the ExAC Database (19). This variation was shared 
in homozygosis in PTIII-1 and PTIII-2 (Figure 1F). Sanger sequenc-
ing validated the c.602C>T SNP and confirmed that it was present 
in homozygosis in the 2 sons and their grandfather (PTI-1) and in 
heterozygosis in both nonaffected parents (PTII-5 and PTII-6) as 
expected for a pseudodominant inheritance due to inbreeding in 
the family. Further screening of 104 patients with a similar clini-
Figure 3. Membrane trafficking of POPDC2 is affected in patients with a homozygous POPDC1S201F mutation. Skeletal muscle biopsies of PTI-1 and PTIII-2 
and 2 controls were immunostained for (A–D) POPDC2 (green signal) and SCGA (red signal). (E) Quantification of the relative intensities of the plasma 
membrane staining of POPDC2 and SGCA in 10 fibers each from 3 sections per biopsy. The signals of POPDC2 and SGCA and the ratio of both were plotted 
relative to the means of both controls, which were set at 1. The normalized intensities revealed a downregulation of the membrane localization of POPDC2 
in the patient material. Scale bars: 10 μm. (F) Western blot analysis of POPDC2 expression in the muscle biopsy material of the 2 controls (CT1 and CT2) 
and PTI-1 and PTIII-2. Results are representatives of 3 independent experiments.
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muscle fibers, suggesting that the S201F mutation predominantly 
causes a reduction in plasma membrane trafficking rather than 
affecting protein expression levels.
The histological analysis and CT scan demonstrated absence 
of severe fibrosis and fat replacement in PTIII-1 and PTIII-2 (Sup-
plemental Figure 1, A–C, and Supplemental Figure 3). However, in 
the grandfather (PTI-1), fiber size variability, central nuclei, and 
plasma membrane discontinuities in muscle fibers were observed 
(Figure 1E and Supplemental Figure 1D). TEM of PTIII-2 failed to 
detect membrane discontinuities or any other abnormality of the 
caveolae, basal membrane, and nuclear pores (data not shown), 
which is in accordance with the late onset of muscle pathology in 
this family. We studied the expression of proteins involved in mem-
brane stability and repair in PTI-1 and PTIII-2 in comparison with 
2 controls (Supplemental Figures 5–9). We previously reported 
protein-protein interaction of POPDC1 with CAV3 (12). However, 
the membrane presence of CAV3 was not altered in the patients’ 
POPDC2 were prominently expressed in the sarcolemma (Figure 
2, A, B, E, and Figure 3, A, B, and E). In contrast, in skeletal muscle 
biopsies of PTI-1 and PTIII-2, a significant reduction in membrane 
localization of both POPDC1 and POPDC2 was observed (Figure 
2, C–E, and Figure 3, C–E). While plasma membrane labeling was 
diminished, an increased perinuclear localization of POPDC1 and 
POPDC2 was observed in the patients’ biopsies (Figure 2, F–Q, 
and Figure 3, C and D). In addition, pronounced expression in cells 
adjacent to the muscle fiber, which may represent activated satel-
lite cells or myoblasts, was observed and particularly prominent 
in cases of POPDC2 in both patients (Figure 3, C and D). The total 
levels of POPDC1 and POPDC2 in muscle biopsies and in dermal 
fibroblast were determined by Western blot analysis (Figure 2, R 
and K, Supplemental Figure 3, and Supplemental Figure 4). The 
expression levels varied slightly between samples; however, total 
protein levels did not correlate with the significant reduction of the 
plasma membrane levels of POPDC1 and POPDC2 in the patients’ 
Figure 4. The POPDC1S201F mutant protein displays a reduced cAMP affinity. (A) cAMP affinity precipitation of WT or POPDC1S201F protein. Left panel: 
precipitated proteins, unbound fraction, and input samples as well as protein subjected to control precipitation using ethanolamine-agarose (agarose) were 
subjected to Western blot detection of POPDC1. Right panel: quantification of cAMP affinity, calculating the ratios between input and cAMP agarose–bound 
protein fractions. (B) Left: example of a FRET measurement of 293A cells transfected with YFP–TREK-1 together with POPDC1-CFP or POPDC1S201F-CFP. Right: 
relative change in FRET signal as a measure of cAMP affinity. (C) Chemiluminescence assay in Xenopus oocytes analyzing the surface expression of extracel-
lularly HA-tagged TREK-1 in the absence or presence of POPDC1 or POPDC1S201F. Control, noninjected oocytes. Measurements after incubation with 0.5 mM 
theophylline are illustrated with white bars. (D) Representative 2-electrode voltage clamp measurements in oocytes injected with TREK-1 alone (black) or 
coinjected with Popdc1 (gray) or POPDC1S201F (red). Voltage was ramped from –110 to +35 mV. (E) Relative current amplitudes at 0 mV. (F) 2-Electrode voltage 
clamp measurements in oocytes injected with TREK-1 or coinjected with POPDC1 or POPDC1S201F bathed after cRNA injection in a storage solution containing 
1 mM 8-Br-cAMP. (G) Relative current amplitudes of TREK-1 coinjected with POPDC1, measured in recording solution or directly after 10 minutes of perfusion 
with 2 mM 8-Br-cAMP. (A–C and E–G) Numbers of experiments are included in the bars. Results are presented as mean ± SEM. Two groups of measure-
ments in A were compared by paired 2-tailed Student’s t test. One-way ANOVA was used for the data presented in B, C, and E–G. *P < 0.05; ***P < 0.001.
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muscle biopsies in comparison with controls (Supplemental Figure 
5). We also studied DYS, which was coimmunoprecipitated with 
POPDC1 (Supplemental Figure 6). However, we could not detect 
any difference in membrane localization between patient and con-
trol samples (Supplemental Figure 7). Membrane discontinuities 
were observed in the muscle biopsy of the grandfather (PTI-1), a 
feature that is typical of dysferlinopathies and related muscle disor-
ders (20, 21). We established association of DYSF with POPDC1 by 
colocalization and coimmunoprecipitation (Supplemental Figure 
8). However, plasma membrane levels of DYSF were not affected in 
patients with a homozygous POPDC1S201F mutation (Supplemental 
Figure 9). These data indicate that POPDC1 does not affect sarco-
lemmal localization of DYS, DYSF, and CAV3. Possibly, these pro-
tein-protein interactions only become essential under particular 
physiological conditions, such as in response to membrane wound-
ing or during muscle regeneration (13).
The POPDC1S201F mutant protein displays a reduction of its affin-
ity for cAMP. The S201 residue is part of the ultraconserved DSPE 
motif, which is essential for cAMP binding (10). We therefore 
assessed whether the change of serine to phenylalanine might 
cause a reduction in cAMP affinity of POPDC1 with the help of 
a ligand precipitation assay, previously utilized for the mouse 
protein (10). We found that the S201F mutant protein has an 
approximately 50% reduction in affinity for cAMP (Figure 4A). 
To corroborate this finding, we employed a bimolecular fluo-
rescence resonance energy transfer (FRET) sensor based on the 
interaction of POPDC1 and TREK-1, analogous to what was previ-
ously described for mouse POPDC1 (10). FRET was observed after 
cotransfection of either CFP-tagged WT POPDC1 or POPDC1S201F 
together with YFP–TREK-1. Upon stimulation with isoproterenol 
(Iso) or forskolin, a small but robust decrease of the FRET ratio was 
observed for WT POPDC1, but changes in the case of POPDC1S201F 
were much weaker (~50%), confirming in an independent assay 
the decreased cAMP sensitivity of the POPDC1S201F mutant (Figure 
4B and Supplemental Figure 10). No decrease of the FRET ratio 
was observed when the cotransfected cells were preincubated with 
propranolol prior to Iso stimulation, demonstrating that the Iso-
induced change in FRET ratio represented a β-adrenergic receptor– 
dependent event (Supplemental Figure 10).
To demonstrate that the different response to rising cAMP lev-
els of mutant and WT POPDC1 is based on different cAMP affini-
ties and not due to an impaired interaction between POPDC1S201F 
and TREK-1, we narrowed down the TREK-1 interaction domain 
using the mouse protein by deletion and coimmunoprecipitation 
analysis (Supplemental Figure 11). The interaction with POPDC1 
was lost when 219 amino acids were deleted from the carboxy ter-
minus. These data suggest that the TREK-1 interaction domain of 
POPDC1 is located between residues 139 and 186 and therefore is 
positioned at some distance from the phosphate-binding cassette 
(residues 198–218). Consequently, it is unlikely that the S201F 
mutation directly affects the interaction of POPDC1 with TREK-1. 
This conclusion is also supported by the observation that both 
mutant and WT POPDC1 colocalize with TREK-1 after cotransfec-
tion (Supplemental Figure 12).
Enhanced surface expression of TREK-1 by POPDC1 is lost by the 
S201F mutation. Enhanced TREK-1 outward currents are observed 
after coexpression of mouse POPDC1 and TREK-1 in Xenopus 
oocytes (10). For mouse POPDC2, we were able to establish that 
the increased outward current of TREK-1 is most likely caused by 
an enhanced surface expression of the channel (10). Here, we show 
that the coexpression of TREK-1 with human POPDC1 also caused 
strongly increased surface expression of the channel (Figure 4C). 
Interestingly, the S201F mutation impaired the ability of POPDC1 
to enhance the surface expression of TREK-1 (Figure 4C). Moreover, 
raising intracellular cAMP levels by the phosphodiesterase inhibi-
tor theophylline resulted in an almost 6-fold increase in surface 
expression of TREK-1 when coexpressed with WT POPDC1. How-
ever, in the presence of the S201F mutant, the surface expression of 
TREK-1 was not affected (Figure 4C). Thus, similar to the impaired 
plasma membrane localization of POPDC2 in the patients’ mus-
Figure 5. POPDC1S201F hyperpolarizes the membrane potential of sponta-
neously beating HL-1 cells. (A) Representative action potentials recorded 
for HL-1 cells or HL-1 cells transfected with POPDC1 or POPDC1S201F. The 
boxes at the bottom represent an enlarged view to show the effects on 
maximal hyperpolarization and afterhyperpolarization. (B) Analyses of 
the action potential duration, analyzed at 50 % of repolarization (APD50). 
(C) Analyses of maximal hyperpolarization (Max. HP), (D) afterhyperpo-
larization (AHP), and (E) activation threshold for HL-1 cells or HL-1 cells 
transfected with POPDC1 or POPDC1S201F. (F) Enlarged view showing the 
upstroke phase of an action potential of HL-1 cells or HL-1 cells transfected 
with POPDC1 or POPDC1S201F. Traces were aligned to the activation thresh-
old. (G) Analyses of the upstroke velocity (Up. vel.). Results are presented 
as mean ± SEM. One-way ANOVA was used to compare multiple variables 
presented in B–E and G. **P < 0.01; ***P < 0.001.
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cle biopsies, membrane trafficking of TREK-1 in Xenopus oocytes 
was affected in the presence of the S201F mutant. Coexpression 
of TREK-1 with POPDC1 led to increased current amplitudes for 
both WT and mutant S201F (Figure 4, D and E). Surprisingly, coex-
pression of the S201F mutant with TREK-1 caused an even more 
pronounced enhancement of TREK-1 outward currents than WT 
POPDC1. While POPDC1 increased TREK-1 currents by 40%, the 
S201F mutant caused an increase of the TREK-1 current by 90%. 
Thus, despite the inability of augmenting TREK-1 surface expres-
sion, the S201F mutant was able to enhance TREK-1 outward cur-
rents, which was presumably caused by an increased conductivity 
of the channels in complex with POPDC1S201F. In the presence of the 
membrane-permeable cAMP analog 8-Br-cAMP, the effects of WT 
POPDC1 on TREK-1 currents were basically abolished (Figure 4F). 
Thus, irrespective of the surface expression, increased cAMP levels 
neutralized the impact of POPDC1 on TREK-1 conductivity (Figure 
4C). Interestingly, perfusion of the oocytes expressing TREK-1 in 
complex with POPDC1 with 8-Br-cAMP (1 mM) during 2-electrode 
voltage-clamp recordings did not affect TREK-1 current amplitudes 
(Figure 4G), indicating that the altered conductivity of the TREK-1/ 
POPDC1 complex is not mediated by a pure gating effect (cAMP 
switch) (9). Most importantly, and consistent with a reduced cAMP 
sensitivity of the mutant protein, POPDC1S201F retained the ability to 
enhance TREK-1 currents even in the presence of 8-Br-cAMP (Fig-
ure 4F). Thus, despite the inability of POPDC1S201F to affect the sur-
face expression of TREK-1 (Figure 4C), the mutant protein caused 
increased TREK-1 outward currents. These seemingly opposing 
effects of the S201F mutant protein to cause impaired channel traf-
ficking while enhancing gating may explain to some extent the car-
diac arrhythmia phenotype in the patients.
Forced expression of POPDC1S201F hyperpolarizes the membrane 
potential of spontaneously beating HL-1 cells. Since POPDC1 is 
predominantly expressed in striated muscle cells, we used HL-1 
cells, which are spontaneously beating sinoatrial node-like myo-
cytes (22), to probe for changes in cellular electrophysiology by 
forced expression of the POPDC1S201F mutant. Both POPDC1 
and POPDC2 are endogenously expressed in HL-1 cells and are 
membrane localized (Supplemental Figure 13). We transfected 
Figure 6. The popdc1S191F zebrafish mutant displays muscular dystrophy and cardiac arrhythmia. (A–D) Confocal analysis of actin (phalloidin staining, red 
channel) and (A and C) DYS (green channel) or (B and D) vinculin (green channel) expression in trunk skeletal muscle of (A and B) WT (popdc1+/+) and (C and 
D) homozygous mutants (popdc1S191F/S191F). Lateral view of the tail musculature in larvae at 5 dpf. Homozygous mutants develop lesions in skeletal muscle. 
Muscle fibers detach from the MTJ and retract. Arrowheads indicate the presence of DYS and vinculin immunoreactivity at the end of the ruptured fibers, 
suggesting that the fibers that have lost connection to the MTJ are probably physically intact. The results shown are representative of 3 independent 
experiments. (E–H) TEM analysis of trunk skeletal muscle of (E and F) WT and (G and H) homozygous popdc1S191F 5-dpf mutant zebrafish embryos. The 
MTJ in the homozygous mutant is characterized by a lack of electron-dense material. The results shown are representative of 3 independent experiments. 
(I–L) Analysis of heart function in WT and homozygous popdc1S191F mutant embryos. (I) Mean heart rate (HR). (J) Mean stroke volume. (K) Percentage of 
embryos displaying a 2:1 AV block. (L) Percentage of embryos displaying a 2:1 AV block after Iso stimulation. Number of embryos in each group is indicated 
on the corresponding bar plot. Results are presented as mean ± SEM. Two groups of measurements in parts I–L were compared by paired 2-tailed Stu-
dent’s t test. *P < 0.05. Scale bars: 10 μm (A–D); 1 μm (E and F); 2 μm (G and H). mf, myofibrils.
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CFP-tagged WT POPDC1 or POPDC1S201F in 
HL-1 cells and recorded action potential prop-
erties of spontaneously beating cells using 
patch-clamp experiments. Forced expression 
of WT POPDC1 into HL-1 cells resulted in a 
pronounced afterhyperpolarization (Figure 5, 
A and D) and shortening of the action poten-
tial duration (Figure 5, A and B) compared 
with nontransfected HL-1 cells. These results 
are well in agreement with the overexpression 
of a TREK-1–activating protein in HL-1 cells, 
as these cells contain endogenous TREK-1 
channels (Supplemental Figure 14). Most 
importantly, transfecting the same amount 
of POPDC1S201F and TREK-1 cDNA caused a 
hyperpolarization of the maximal diastolic 
membrane potential (Figure 5, A and D). 
This effect is in agreement with a more pro-
nounced activation of TREK-1 channels by 
POPDC1S201F (Figure 4, D and E). As cells with 
POPDC1S201F were more hyperpolarized (Fig-
ure 5C) and the activation threshold was also 
shifted to more negative membrane potentials 
(Figure 5E), there was a reduced afterhyper-
polarization compared with WT POPDC1 
(Figure 5D). The more hyperpolarized maxi-
mal diastolic membrane potential might lead 
to an increased availability of sodium chan-
nels in these cells (23, 24). This assumption is 
in agreement with the observation of a more 
hyperpolarized activation threshold (Figure 
5E) and the increased upstroke velocity (Fig-
ure 5,F and G) in HL-1 cells transfected with 
POPDC1S201F. In summary, the overexpression 
experiments in HL-1 cells demonstrate that 
the mutant is more efficient than WT protein 
at raising potassium conductance in these 
Figure 7. Expression of Popdc1 and Popdc2 in 
the trunk skeletal muscle of the adult zebrafish. 
(A and B) Transversal sections through the trunk 
skeletal muscles of WT (popdc1+/+) and homozygous 
popdc1S191F mutants (popdc1S191F/S191F) were stained 
with antibodies for α-dystroglycan and (A) Popdc1 or 
(B) Popdc2. Scale bars: 10 μm. (C and D) Quantifica-
tion of the plasma membrane staining of (C) Popdc1 
and (D) Popdc2 in WT and homozygous Popdc1S201F 
mutant animals, respectively. The regions of inter-
est of 30 fibers were analyzed for each sample. 
The membrane localization of both Popdc1S191F and 
Popdc2 is reduced in the popdc1S191F/S191F mutants. In 
agreement with the reduction in plasma membrane 
localization, increased amounts of the Popdc1S191F 
mutant protein are found in cytoplasmic vesicles 
(arrowheads in A). For statistical testing, mean 
values of the Popdc/dystroglycan ratios of WT (n = 3) 
and mutants (n = 3) were compared by paired 2-tailed 
Student’s t test (C and D). *P < 0.05.
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extracellular matrix (ECM) in the MTJ at 5 dpf (Figure 6, E and G). 
In addition to the MTJ phenotype, a severe reduction in myofibril-
lar content and disarray was also observed (Figure 6, F and H).
We assessed cardiac performance using optical recording, 
which revealed an overall reduction in heart rate and stroke volume 
(Figure 6, I and J). Between 5 dpf and 9 dpf, a steadily increasing 
number of homozygotes developed a 2:1 AV block (Figure 6K). In 
addition, more severe forms of AV block such as 3:1 and even longer 
pauses including electrically silent ventricles were also observed in 
homozygotes (Supplemental Figure 18 and Supplemental Video 3). 
The arrhythmia phenotype displayed a reduced penetrance, with 
approximately 5%–10% of the embryos being affected. Interest-
ingly, Iso induced an approximately 3-fold increase in the number 
of homozygous mutant embryos developing cardiac arrhythmia, 
an effect that was not observed in WT embryos (Figure 6L). Since 
a majority of mutants developed into adulthood, we asked whether 
adult popdc1s191f mutants also displayed any pathology. To this end, 
we confined our analysis to skeletal muscle and studied membrane 
localization of Popdc1 and Popdc2. Adult homozygous mutants 
and WT animals were randomly picked, and Popdc1 and Popdc2 
expression were assessed immunohistochemically in the trunk 
musculature. Similar to what we observed in patients’ biopsies, 
membrane localization of Popdc1 and Popdc2 was significantly 
diminished in the mutant muscle (Figure 7, A–D). In addition, many 
mutant fibers displayed an increase in number and signal intensity 
of immunostained intracellular vesicles, particularly in the case of 
Popdc1 (Figure 7A), suggesting that the serine 191 to phenylalanine 
mutation in zebra fish resulted in impaired membrane trafficking 
of the mutant Popdc1 protein and Popdc2. Therefore, the pheno-
typic spectrum of the homozygous popdc1S191F mutant was reminis-
cent of the phenotypes observed in our patients, fully supporting 
the notion that the POPDC1S201F mutation is pathogenic and causes 
heart and muscle disease.
Discussion
Our work demonstrates that mutations in POPDC1 are respon-
sible for heart and muscle pathologies. Indeed, WES identified 
the disease-segregating homozygous missense mutation S201F in 
POPDC1 in a family with LGMD and AV block. Further screening 
of POPDC1 mutations in 104 patients with heart and/or myopath-
ic phenotypes resulted in a negative outcome for the presence of 
homozygous or compound heterozygous mutations, as expected 
for a very rare, family-specific recessive allele.
Evidence for the pathogenic nature of the POPDC1S201F muta-
tion was in particular obtained by the knockin mutation in zebra-
fish, which displayed several heart and muscle pathologies that 
were reminiscent of the symptoms found in the patients. Further-
more, the in vitro assays provided strong evidence for an essential 
role of cAMP binding to execute POPDC1’s biological functions. 
cAMP-affinity precipitation and FRET analysis revealed that the 
switch from serine to phenylalanine caused an approximately 50% 
reduction in cAMP binding. Further evidence for reduced cAMP 
sensitivity and the resulting electrophysiological consequences was 
obtained from experiments in Xenopus oocytes and HL-1 cells. The 
fact that Iso stimulation caused an increase in the number of zebra-
fish mutants displaying cardiac arrhythmia suggests that the cAMP-
binding ability of POPDC1 has an important physiological function 
cardiac myocyte-like cells, leading to increased hyperpolarized 
membrane potentials. These effects might explain the AV block 
observed in patients and in the POPDC1S191F zebrafish mutant 
(see below), as hyperpolarization of cells in the AV node will fur-
ther delay the propagation of excitation to the ventricles.
Loss of popdc1 in zebrafish causes an impairment of heart and 
skeletal muscle development. Zebrafish popdc1 is expressed in both 
skeletal muscle and heart (Supplemental Figure 15, A–C). To 
assess popdc1 function in zebrafish, a morpholino-based knock-
down approach targeting the splice junctions of exon 4 was uti-
lized. Morpholino injection caused a significant reduction of 
popdc1 mRNA expression (Supplemental Figure 15D). Macroscop-
ically, the morphants appeared normal overall, with the excep-
tion of the presence of a cardiac edema in a large fraction of the 
injected embryos (70%) (Supplemental Figure 15, E and F). Some 
morphants (20%) displayed a 2:1 AV block, a phenotype that has 
been previously reported for popdc2 morphants (Supplemental 
Figure 15G, Supplemental Videos 1 and 2, and ref. 15). Upon closer 
inspection, skeletal muscle was also affected in 80% of the mor-
phants and was characterized by myofibrillar misalignment and 
fiber detachment (Supplemental Figure 15H). The myotendinous 
junction (MTJ) forms the attachment site for muscle fibers, and 
was found to be malformed in the morphants and possibly the 
cause for the fiber detachment (25). Forced expression of mutant 
and WT POPDC1 was achieved by mRNA injection into fertilized 
zebrafish eggs. WT POPDC1 did not affect cardiac morphology; 
however, forced expression of POPDC1S201F caused myocardial 
edema formation indicative of embryonic heart failure (Supple-
mental Figure 16, A and B).
In order to directly test the pathogenicity of the POPDC1S201F 
mutation, we generated by TALEN-mediated gene editing a 
genomic mutation of the corresponding serine residue in zebra-
fish popdc1 (i.e., popdc1S191F). The homozygous popdc1S191F mutant 
developed normally during embryogenesis, and no significant 
lethality in comparison with WT embryos was observed (data not 
shown). However, a significant fraction of homozygotes developed 
cardiac and skeletal muscle phenotypes (Supplemental Figure 17). 
Mutants displayed cardiac edema and aberrant formation of the 
trunk musculature, and, in the most severely affected embryos, an 
edema involving the entire larval body was observed. The mutant 
phenotype displayed a reduced penetrance of approximately only 
one-third of the embryos, which appeared to be affected at 5 days 
post fertilization (dpf). Thus, a majority of homozygotes developed 
into adulthood. One of the reasons for the reduction in phenotype 
penetrance was the presence of 3 family members that at least par-
tially were able to functionally substitute for each other (9).
In order to further study the skeletal muscle phenotype, 
zebrafish larvae at 5 dpf were stained with phalloidin together 
with vinculin or DYS. The trunk skeletal muscle of some homo-
zygous popdc1s191f mutants displayed myofibrillar misalignment, 
aberrant formation of the MTJ, and myofiber detachment, prob-
ably secondary to the impaired MTJ formation, with various 
degrees of severity (Figure 6, A–D). Myofiber detachment is a 
hallmark of muscular dystrophy phenotypes in zebrafish and 
was previously reported, for example, for the DYS mutant sapje 
(26). TEM of trunk muscle development in the homozygous 
popdc1s191f mutant demonstrated an almost complete absence of 
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could be explained by the fact that cAMP not only binds POPDC1, 
but also activates other effector proteins. For example, it is well 
established that protein kinase A interferes with TREK-1 gat-
ing through phosphorylation (30, 31). Our unpublished mapping 
data place the POPDC1-binding site in the vicinity of the PKA-
dependent phosphorylation site of TREK-1. It is therefore possible 
that binding of POPDC1 to TREK-1 results in steric interference 
with PKA-dependent phosphorylation, thereby indirectly shield-
ing TREK-1 from PKA-mediated inactivation. Experiments with a 
TREK-1 mutant, which lacks the PKA-dependent phosphorylation 
site, or pharmacological studies using PKA inhibitors will be infor-
mative in this context (32). Interestingly, POPDC1 is also subject 
to β-adrenergic–dependent phosphorylation (33, 34). Thus, the 
regulation of POPDC1 involving cAMP binding, subcellular local-
ization, and phosphorylation of itself and of interacting proteins 
deserves further investigations.
POPDC1S201F causes a mild, late-onset LGMD. The pathogen-
esis of the muscle damage is supported by the muscular dystrophy 
phenotype that we observed in a significant fraction of homozygous 
popdc1S191F zebrafish mutants. Detachment of muscle fibers from 
the MTJ was evident, as reported in many other zebrafish mutants 
with dystrophic phenotypes (25, 26, 35–37). The myofiber detach-
ment is probably based on the failure of proper ECM formation, as 
demonstrated by TEM. It can be envisioned that the lack of proper 
matrix assembly provides insufficient mechanical linkage, leading 
to fiber detachment when the zebrafish larvae start to swim. Iden-
tical phenotypes were observed for popdc1 (this study and Supple-
mental Figure 14) and popdc2 morphants (15), suggesting that both 
genes are probably acting together in the same pathway. Presently, 
it is unclear how POPDC proteins are linked to MTJ formation and 
ECM accumulation and what role cAMP signaling might have in 
these processes; however, the fact that POPDC1 interacts with DYS 
(and DYSF and CAV-3) suggests that it might be involved in lam-
inin-DAG linkage formation (37, 38). In skeletal muscle, laminins 
connect the muscle cell to the ECM by binding either dystroglycan 
or integrins at the cell membrane. Epistasis experiments will be 
required to find out whether POPDC1 is interacting with dystrogly-
can (possibly via DYS), integrins, or both. Alternatively, POPDC1 
may be involved in matrix deposition, as POPDC1 has recently 
been implicated in autocrine matrix deposition (39).
In conclusion, we have discovered a disease gene, POPDC1, 
causing a very rare LGMD with recessive inheritance and mild dis-
ease progression in skeletal muscle. However, the heart is strongly 
affected by this mutation, producing a severe form of AV block. 
Aberrant membrane trafficking and ECM abnormalities probably 
form the molecular basis for the observed heart and skeletal mus-
cle phenotypes present in this family. The functional interaction of 
POPDC1 with a variety of membrane and membrane-associated 
proteins opens up perspectives for studying the genetic basis of 
cardiac and skeletal muscle disease and other phenotypes that are 
related to the main or corollary functions of POPDC1.
Methods
WES. Exome sequencing was performed using genomic DNA of the 2 
affected brothers (PTIII-1 and PTIII-2) and both parents using Nimble-
Gen Sequence Capture technology (SeqCap EZ Human Exome Library 
v2.0) according to the manufacturer’s instructions. The enriched librar-
in the heart. The sarcolemmal localization of the mutant protein was 
reduced in the patients’ muscle biopsies and in the trunk muscula-
ture of the zebrafish mutant. These data suggest that cAMP bind-
ing of POPDC1 is somehow involved in modulating its own mem-
brane transport. Moreover, membrane trafficking of TREK-1 was 
impaired in the presence of mutant POPDC1S201F protein. Similarly, 
POPDC2 displayed a trafficking defect in muscle tissue, suggesting 
that cAMP binding of POPDC1 not only modulates its own mem-
brane trafficking, but also that of associated proteins. Mutations in 
POPDC1, which cause a lack or a reduction in cAMP affinity, may 
actually result in a gain of function, increasing hyperpolarization 
and upstroke velocity of the cardiac action potential. Both param-
eter changes could be interpreted as effects of POPDC1 on TREK-1 
current. However, it is unlikely that TREK-1 alone is sufficient 
to fully explain the clinical phenotypes observed in the patients. 
Nonetheless, this protein-protein interaction served throughout our 
study as a surrogate to assess POPDC protein family function. Fur-
ther work will be required to identify additional POPDC interaction 
partners; this may provide additional opportunities to better define 
the molecular basis for the observed cardiac arrhythmia phenotype.
Markedly, impaired membrane trafficking was reported in 
many forms of muscular dystrophy, especially those caused by 
mutations in CAV3, DYS, and DYSF (27). However, no discern-
ible effects on the plasma membrane levels of these proteins were 
observed in our patients, despite the fact that each of them was 
coimmunoprecipitated with POPDC1. The effects of POPDC1 on 
CAV3, DYS, and DYSF may be subtle and not discernible by immu-
nohistochemistry. We may speculate that these interactions might 
be more important in response to plasma membrane rupture or 
during muscle regeneration (13). Therefore, the physiological and 
pathophysiological roles for these protein-protein interactions 
have yet to be defined.
The Xenopus oocyte experiments demonstrated a dual impact 
of POPDC1 on TREK-1, with both processes being modulated by 
cAMP. We observed a cAMP-dependent increase in membrane 
localization of TREK-1 as well as a decrease in channel gating. We 
recently proposed 2 alternative models to describe how POPDC1 
might modulate ion channel function: the switch and the cargo 
model (9). The cargo model proposes that POPDC1 might be 
involved in membrane trafficking. Our data give further support 
to this model, since cAMP binding to POPDC1 causes an increase 
in membrane localization. It is noteworthy that an interaction of 
POPDC1 with the vesicle-associated membrane protein VAMP3 
has recently been reported (28). However, the significance of this 
interaction with regard to the regulation of membrane localization 
in skeletal muscle is presently unclear and deserves further study.
The switch model predicts that cAMP binding induces a 
conformational change in the POPDC1 protein, affecting the 
biological properties of interacting proteins. Ligand-induced 
conformational changes have been described for other cAMP 
effector proteins (29), and the POPDC1/TREK-1 FRET data 
suggest a similar structural remodeling in the case of POPDC1 
However, the switch model is not supported by the fact that the 
TREK-1 current in oocytes is not acutely affected by cAMP, sug-
gesting a more complex regulation. Furthermore, in the presence 
of S201F, membrane transport of TREK-1 is impaired; however, 
an increase in current can be measured. These paradoxical results 
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mouse (A31570, Invitrogen). For counterstaining, DAPI (Calbiochem) 
was employed. The fluorescent signal was analyzed by confocal micros-
copy. Membrane signal intensities of approximately 30 muscle fibers 
were measured using Icy software and corrected for background. To 
calculate relative signal intensity levels, individual measurements from 
mutant fibers and control fibers were taken as a percentage of mean of 
control samples. Error bars are to 1 SD.
Immunocytochemistry. Cos-7 cells (87021302, Sigma-Aldrich) 
were transfected with constructs encoding HA-tagged POPDC1WT or 
POPDC1S201F alone or together with a TREK-1–Flag plasmid or myc-
tagged mouse POPDC1 together with HA-tagged DYSF and stained 
24 hours later with anti-HA (MMS-101R, Covance), anti-Flag (F1804, 
Sigma-Aldrich), or anti-myc (clone 9c,10, ab32 Abcam) antibodies. As 
secondary antibodies, FITC-conjugated anti-mouse Fab fragments 
(715-097-003, Jackson ImmunoResearch Laboratories) and Alexa 
Fluor 555–conjugated donkey anti-mouse (A31570, Invitrogen) were 
used. HL-1 cells (provided by Emmanuel Dupont, Imperial College 
London) were stained using anti-POPDC1 (HPA018176, Sigma-
Aldrich) and anti-POPDC2 (HPA024255, Sigma-Aldrich) as primary 
and Alexa Fluor 594–conjugated donkey anti-rabbit (A-21207, Invitro-
gen) as secondary antibodies. Nuclei were stained with DAPI (Calbio-
chem). Images were taken using a Zeiss LSM 510 confocal microscope.
Live cell imaging (FRET analysis). 293A cells (R705-07, Thermo Fisher 
Scientific) were transfected with POPDC1WT-CFP or POPDC1S201F-CFP 
together with YFP–TREK-1 plasmids at a 5:1 ratio. Forty-eight hours later, 
live cell imaging was performed exactly as described previously (10).
Mutagenesis. The S201F point mutation was introduced into 
POPDC1 cDNA by PCR using the following primers: POPDC1-S201Fs, 
5′-AACATTTACCCCTGTGCCTTTAT AGATTTTCCTGAATTTA-
GATCAAC-3′; POPDC1-S201Fas, 5′-GTTGATCTAAATTCAGGA-
AAATCTATAAAGGCACAGGGGTAAATGTT-3′ (mutant nucleotides 
are underlined). Correct mutagenesis was confirmed by sequence 
analysis. For injection into Xenopus oocytes and zebrafish eggs, 
cDNAs were subcloned into pSGEM. For expression in mammalian 
cell lines, cDNAs were subcloned into the pECFP-N1 vector (Clon-
tech). PCR was used to generate POPDC1 constructs that encode pro-
teins fused at their carboxy termini to a HA epitope tag.
Tissue lysates. For determining expression levels, proteins were 
extracted from skeletal muscle using 50 mM Tris, pH 8.0, 4 M urea, 10% 
SDS, and 2 mM EDTA, pH 8.0. Protein concentrations of lysates were 
estimated with the help of the DC Protein Assay (Bio-Rad), and equal 
amounts of proteins were subjected to gel electrophoresis and Western 
blot analysis. To reduce protein aggregation, lysates were incubated at 
37°C for 30 minutes or 60°C for 15 minutes in SDS loading buffer.
cAMP-affinity precipitation. Cos-7 cells (87021302, Sigma-
Aldrich) were transfected with POPDC1WT or POPDC1S201F constructs 
with HA epitope tags attached to their C termini using Lipofectamine 
2000 reagent (Invitrogen), and cells were harvested 24 hours later 
using a buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 2 mM 
EDTA, pH 8.0, 1% (v/v) Triton X-100, 0.25% (w/v) gelatin, and 
protease inhibitors (Roche). Cell lysates were briefly sonicated and 
cleared twice by centrifugation at approximately 18,000 g at 4°C for 
30 minutes. Then 30 μl of the lysates were taken as loading controls. 
Lysates were first incubated with 50 μl ethanolamine (EtOH-NH) 
agarose (BioLog) for 1 hour with rotation at 4°C. After centrifuga-
tion at 500 g at 4°C for 5 minutes, the supernatant was supplemented 
with 1 mM IBMX (3-isobutyl-1-methylxanthine; Sigma-Aldrich) and 
ies underwent 90 base pair, paired-end sequencing on a HiSeq2000 
next-generation sequencing platform (Illumina) at an average of 80× 
coverage. SOAPaligner (soap2.21) was used to align clean reads to 
the human reference genome (UCSC hg19, build 37.1), and SNP call-
ing used the SOAPsnp (v.1.03), while BWA and the Genome Analysis 
Tool Kit (GATK) were used for the detection of indels. After filtering 
PCR duplicates, some public databases, including dbSNP135 (with fre-
quency greater than 0.5%), 1000 Genome variants database, HapMap 
exomes, and an in-house database, which contains WES data from 
approximately 1,000 normal individuals, were used to filter out previ-
ously reported variants. As disease-causing variants have a very high 
probability of causing amino acid changes, we initially focused on non-
synonymous variants and splice-site and indel mutations. For potential 
disease-causing variants, the consequences of the amino acid changes 
were predicted using Polyphen2 (40), SIFT (41), and Pmut (42). In 
order to confirm that the variation was not the product of sequenc-
ing errors, PCR amplification and Sanger sequencing were performed 
on the variant. Primer pairs to amplify the sequence surrounding the 
mutation were synthesized (POPDC1 Exon 4–forward, AAATACTT-
GTGCCTCAAGAAGTGC; POPDC1 Exon 4–reverse, CCCCCAATA-
ATTCATAGCAGTG), and the PCR was run in a final volume of 25 μl 
containing 100 ng genomic DNA, 20 mM Tris–HCl (pH 8.4), 50 mM 
KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 5 U Taq DNA Polymerase (Invi-
trogen), and 0.4 μl of each primer. The amplified PCR product was 
analyzed by direct sequencing on an automatic sequencer (ABIPRISM 
3130, Applied Biosystems). DNA library construction and target cap-
ture were performed following the manufacturer’s protocol before 
sequencing on the SOLiD 5500xl (Life Technologies) using a paired-
end protocol (read length 75 bp + 35 bp). Reads were demultiplexed 
and aligned to a human reference genome (hg19). Duplicate reads and 
those with low mapping quality score (<8) were removed. Variant call-
ing was carried out using diBayes (SNPs) and small indel modules as 
well as GATK v1.5-20 and Samtools v0.1.18. Alignment and coverage 
metrics were calculated using Picard v1.40, BedTools v2.12, and in-
house Perl scripts. GATK CallableLoci Walker was used to identify tar-
get genomic regions covered sufficiently for variant calling (minimum 
depth > 4 with base quality > 20 and mapping quality > 10).
POPDC1 mutation screening in patients. We screened an additional 
104 unrelated patients with different clinical features, including cardi-
ac arrhythmia, AV block, sudden death, and LGMD (see Supplemental 
Table 1), for mutations in POPDC1. Genomic DNA from patients was 
extracted from peripheral lymphocytes by standard methods. PCR 
primers (Supplemental Table 2) were designed to amplify all 7 exons 
of POPDC1 as well as their flanking intronic regions. PCRs were run 
and analyzed under the conditions described above.
Immunohistochemistry. The 10-μm frozen sections of skeletal 
muscle biopsies of patients PTI-1 and PTIII-2 and 2 control biopsies or 
muscles dissected out from adult WT and popdc1S191F/S191F zebra fish were 
mounted on Superfrost Plus glass slides (Thermo Fisher Scientific) and 
subjected to immunohistochemistry using the following primary anti-
bodies: POPDC1 (HPA018176, Sigma-Aldrich), POPDC2 (HPA024255, 
Sigma-Aldrich), DYS (D8043, Sigma-Aldrich), CAV3 (610420, BD 
Transduction Laboratories), DYSF (NCL-Hamlet, Leica), α-sarcoglycan 
(NCL–α-SARC, Leica), and dystroglycan (MANDAG2[7D11], DSHB). 
For the detection of primary antibodies, the following secondary anti-
bodies were employed: Alexa Fluor 488–conjugated donkey anti-rabbit 
(A-21206, Invitrogen) and Alexa Fluor 555–conjugated donkey anti-
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Gene editing. A popdc1S191F mutation was generated using the Gol-
dyTALEN modified scaffold (46). The left TALEN (P1E5_S191FL: 
5′-AACATTTTACACCAATGCCTT-3′) and right TALEN (P1E5_
S191FL: 5′-CATCTGAGTTGACCTGAA-3′) were assembled via 
the GoldenGate method. For ease of analysis, TALEN recognition 
sequences flanked a PleI restriction site in exon 5 of popdc1, which was 
destroyed upon successful targeting. TALEN repeat variable di-resi-
dues (RVDs) were cloned into a pT3TS-driven TALEN scaffold. Result-
ing mRNA was injected into 1-cell–stage zebrafish embryos. For S191F 
mutagenesis, the following oligonucleotide was coinjected together 
with the TALEN constructs: S191F oligonucleotide, CACCAAT-
GCCTTCATCGACTTCCCAGAATTCAGGTCAA (underlined triplet 
encodes F191; bold letters indicate which nucleotides were mutated). 
Larvae were molecularly tested at 2 dpf or raised for germline muta-
tion analysis. Somatic and germline TALEN-induced mutations were 
evaluated by PCR and restriction fragment length polymorphisms. 
The primer pair P1TALE5_1434F, 5′-TCAGAAATCCAGACAGCC-
GTG-3′ and P1TALE5_2175R, 5′-AGTTCTCCTCAGCAGCGATC-3′ 
was used to amplify the locus. Subsequently, the PCR fragment was 
restriction digested with PleI. The mutant allele produced a 741-bp 
fragment, while the WT allele produced 2 fragments of 365 and 375 
bp. For further analysis, the PCR products were sequenced with the 
following primer sequences: P1TALE5_1556F, 5′-CAAAACAATAATG-
GCAGACTG-3′ and P1TALE5_2069R, 5′-TCTTTTTTATTTGTGT-
GTAGGGAA-3′. Heterozygotes were backcrossed 6 times with the 
AB line in order to outcross any off-target mutations. Homozygous 
mutant and WT animals were bred separately.
Forced expression. The human POPDC1WT and POPDC1S201F cDNAs 
were subcloned into the psGEM vector. To generate mRNA, the clones 
were linearized with XhoI and capped mRNA was synthesized using 
the T7 mMessage Machine Kit (Ambion).
Whole-mount in situ hybridization. Whole-mount in situ hybrid-
ization was carried out as described previously (15). A partial clone of 
popdc1 cDNA was subcloned into the pGEMTeasy vector (Promega). 
A digoxygenin-labeled antisense probe was generated using T3 poly-
merase after linearization with BamHI.
Whole-mount immunohistochemistry and rhodamine-phalloidin 
staining. Whole-mount immunostaining was performed as described 
previously (15). The following primary antibodies were used: mono-
clonal F59 (DHSB), monoclonal F310 (DHSB), monoclonal anti-
sarcomeric α-actinin (A7811, Sigma-Aldrich), anti-DYS (D8043, 
Sigma-Aldrich), and anti-vinculin (FAK100, Millipore). Alexa Fluor 
488–coupled donkey anti-mouse (A21202, Invitrogen) was used as 
secondary antibody. For F-actin staining, zebrafish embryos were 
incubated with rhodamine-phalloidin (R415, Invitrogen). Stained 
zebrafish embryos were embedded in 1% low melting agarose and 
imaged by confocal microscopy (Zeiss, LSM 510).
Live in vivo cardiac imaging. The heart rate of zebrafish morphants 
was recorded using a Leica imaging system equipped with a VGA Min-
iature GigE CCD Color Camera (DFK 23G618, Scorpion Vision). Video 
images were recorded at 28°C and processed with ImageJ (43) to obtain 
heart rate measurements and perform M-mode analysis. For in detail 
analysis of the arrhythmic phenotype, cardiac performance batches 
were screened for individuals showing arrhythmic phenotypes without 
cardiac edema. Cardiac contractility was recorded in tricaine-anesthe-
tized 6- to 9-dpf embryos. For pharmacological characterization of the 
phenotype, 50 homozygous Popdc2S181F individuals were incubated in 
added to 4.8 mg cAMP agarose (A0144, Sigma-Aldrich). After incu-
bation for 2 hours with rotation at 4°C, both EtOH-NH and cAMP 
agaroses were washed with wash buffer A (10 mM HEPES, pH 7.4, 
1.5 mM MgCl2, 10 mM KCl, 500 mM NaCl, 0.1% [v/v], Igepal 
CA-630, 1 mM DTT, 1 mM IBMX) followed by 3 washes with wash 
buffer B (10 mM HEPES, pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.1% 
[v/v], Igepal CA-630, 1 mM DTT). Agarose-bound proteins were 
eluted in SDS sample buffer by boiling at 96°C for 5 minutes and sub-
jected to gel electrophoresis and Western blot.
Gel electrophoresis and Western blot. Proteins were size separated 
and transferred onto nitrocellulose membrane (BioTrace NT, Pall). 
The membrane was washed with TBST (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 0.1% [v/v] Tween-20) and blocked in 5% (w/v) low-fat milk 
in TBST for 1 hour at room temperature and subsequently incubated 
with anti-HA (MMS-101R, Covance), anti-FLAG (F1804, Sigma-
Aldrich), anti-actin (sc-1616, Santa Cruz Biotechnology Inc.), anti-
POPDC1 (sc-49889, Santa Cruz Biotechnology Inc.), or anti-POPDC2 
(HPA024255, Sigma-Aldrich) overnight at 4°C. For peptide competi-
tion assays, membranes were incubated with POPDC1 or POPDC2 
antibodies together with a 10-fold excess of the respective neutraliz-
ing peptide (sc-49889 P [POPDC1], Santa Cruz Biotechnology Inc., 
APrEST72859 [POPDC2], Atlas Antibodies). After several washes, the 
blots were incubated for 1 hour at room temperature with horseradish 
peroxidase–coupled anti-mouse (PI-2000, Vector Laboratories), anti-
goat (PI-9500, Vector Laboratories), or anti-rabbit antibodies (PI-
1000, Vector Laboratories). After washing, signals were detected using 
an enhanced chemiluminescence protein detection method (Milli-
pore). Exposed films were digitalized and band intensities were deter-
mined using ImageJ (43). Ratios between input and cAMP agarose– 
bound protein fractions were calculated and values were statistically 
analyzed using GraphPad Prism.
Coimmunoprecipitation analysis. For coimmunoprecipitation (Co-
IP) analysis, Cos-7 cells (87021302, Sigma-Aldrich) were transiently 
transfected with myc-tagged Popdc1 and either Becker DYS, M2-micro-
dystrophin (provided by Rolf Stucka, Ludwig-Maximilans-Universität, 
Munich, Germany), FLAG-tagged Dp71 DYS (GenScript), or DYSF-
3HA provided to Addgene (plasmid catalog 29767) by Steven Vogel 
(NIH, Bethesda, Maryland, USA) (44); empty vectors were transfected 
as negative controls. Protein lysates were produced as described above. 
A sample was taken as input control, and the rest of the lysates were 
subjected to Co-IP using the ProFound c-Myc Tag IP/co-IP Kit (23620, 
Thermo Fisher Scientific) or the Pierce HA Tag IP/Co-IP Kit (26180, 
Thermo Fisher Scientific) following the manufacturer’s instructions.
Zebrafish strains and lines. Zebrafish AB and popdc1S191F lines were 
maintained under standard conditions at 28.5°C according to estab-
lished protocols (45). Zebrafish were raised and staged in hours post 
fertilization (hpf) or dpf. Pigmentation was inhibited with 0.2 mM 
1-phenyl-2-thiourea (PTU) in egg water.
Morpholino design and microinjections. Morpholino-modified oli-
gonucleotides (MO) were obtained from Gene Tools LLC. Embryos 
were injected at the 1- to 2-cell stage with 0.5 ng to 2 ng of popdc1- 
specific morpholino; coinjection of p53-targeting morpholino (5′-GCG-
CCATTGCTTTGCAAGAATTG-3′) was performed to suppress nonspe-
cific morpholino toxicity. Morpholinos targeting popdc1 were directed 
against the splice-acceptor site of exon 4 (MO1-popdc1, 5′-CTTAATC-
TGGAATTAAACAGGAGAA-3′) and the splice donor site of exon 4 
(MO2-popdc1, 5′-TACTTTCCTTTGAGAAGAATGCTGA-3′).
Downloaded from http://www.jci.org on February  3, 2017.   https://doi.org/10.1172/JCI79562
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 5 1jci.org   Volume 126   Number 1   January 2016
NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.33 mM NaH2PO4, 10 
mM glucose, 2 mM sodium pyruvate, and 5 mM HEPES (pH 7.4 with 
NaOH) as previously described (49, 50). Patch-clamp experiments 
were performed in the whole-cell configuration using pipettes pulled 
from borosilicate glass capillaries. The pipettes had a tip resistance 
of 3.0 to 4.0 MΩ when filled with a solution containing 60 mM KCl, 
65 K+-glutamate, 5 mM EGTA, 2 mM MgCl2, 3 mM K2ATP, 0.2 mM 
Na2GTP, and 5 mM HEPES (pH 7.2 with KOH). Data acquisition and 
command potentials were controlled with a commercial software pro-
gram (Patchmaster, HEKA) with a sweep time interval of 1 second and 
a sample rate of 200 kHz. Data analysis of action potentials was done 
using Fitmaster software (HEKA). For each cell measured, the action 
potential parameters were averaged by analyzing 10 subsequent 
action potentials, as previously described (49).
RT-PCR. Total RNA was isolated from HL-1 cells using High Pure 
RNA Isolation Kit (Roche) containing DNAseI. Reverse transcription 
(RT) was performed with Superscript II reverse transcriptase (Invitro-
gen) according to the manufacturer’s instructions. PCR was performed 
using Taq Gold Polymerase (Applied Biosystems) according to the man-
ufacturer’s instructions. Reaction mixtures were preheated at 96°C for 
5 minutes, followed by 40 cycles at 96°C for 30 seconds, 58°C for 30 sec-
onds, and 72°C for 45 seconds. PCR products were visualized by gel elec-
trophoresis on 2% agarose gels. The following intron-spanning primers 
were used: GAPDH forward, 5′-ACTTCAACAGCAACTCCCACTCT-3′, 
GAPDH reverse, 5′-GCTGTAGCCGTATTCATTGTCATA-3′; TREK-1 
forward, 5′-G ACGAACTCATCCAGCAAATAGTG-3′, TREK-1 reverse, 
5′-AAAGAAGAAAGAGCTTCCGAGGTC-3′. For both primer pairs, the 
amplification products were confirmed by sequencing. RNA that was 
not reverse transcribed was used as negative control.
Statistics. Results are presented as mean ± SEM. Statistical signifi-
cance was defined as P < 0.05.
Study approval. Informed consent for WES analysis and clinical 
exome analysis for the family was obtained. Approval of the Ethical 
Committee University Hospital Ferrara was given to the project as fol-
lows: Neuromics, approved May 30, 2013, approval number 05/2013, 
P. 58-2013; RARER, approved June 20, 2013, approval number 
06/2013, P. 95-2013 and routine molecular diagnosis approval num-
ber 26/7/2012, P. 7/2012. The zebrafish work at Imperial College Lon-
don was approved by the Animal Welfare and Ethical Review Board 
of the Harefield Heart Science Centre and licensed by the United 
Kingdom Home Office (PPL 70/7171). The zebrafish work at the Uni-
versity of Innsbruck was approved by the Austrian Bundesministerium 
für Bildung, Wissenschaft, und Kultur (animal ethics permission GZ 
66.008/0004-II/3b/2012). The work with Xenopus at the University 
of Marburg was approved by the Regierungspräsidium Gießen, Ger-
many (V54-19c 20 15 hours 02 MR 20/28 Nr.A 4/2013).
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EB clinically characterized the family. AP clinically supervised the 
project on the families of 4 (RARER). CR and EA clinically charac-
terized the patients with cardiac abnormalities screened for muta-
tions. CS, CP, FRDR, RS, FG, MN, WL, HJ, and XX performed the 
DNA studies, patient screening, and technical validation. JZ and 
MF performed the WES and bioinformatics analysis. JW designed 
WES studies. ND designed and analyzed the electrophysiological 
10–4 M Iso (experimental group) or water (control) for 5 minutes. The 
percentage of animals displaying cardiac arrhythmia was determined. 
The imaging system consisted of a custom-made selective plane illu-
mination microscope (SPIM) equipped with an Olympus UMPLFLN 
20 × W objective and a digital high-speed video camera, Hamamatsu 
Orca Flash 4.0, in transmitted light mode. Images were recorded at 
28°C (2,000 images, 100 fps) and imported into Fiji (47). Luminance 
periodograms of pixels being passed by the ventricle or atrium were fil-
tered by an equi-ripple low-pass filter with a pass frequency of 0.1 Hz 
and a stop frequency of 10 Hz (Lab View 2013, National Instruments). 
In these filtered periodograms, peaks were detected and peak-to-peak 
distances (reflecting beat-to-beat distances) were converted to a beat-
to-beat frequency for each interval. These frequencies were plotted 
against time to a cardiotachiogram to calculate mean heart rate. Stroke 
volume was determined as described (48).
TEM. Five-dpf WT or popdc1S191F/S191F zebrafish larvae were sacri-
ficed using MS-222 and fixed in 2.5% (v/v) glutaraldehyde in 0.1 M 
sodium cacodylate buffer (pH 7.4) at 4°C overnight and then postfixed 
in 1% (w/v) osmium tetroxide in 0.1 M sodium cacodylate buffer at 
room temperature for 1 hour. After 2 buffer washes, samples were 
dehydrated using a graded ethanol series of 50%, 70%, 90%, and 
100% (v/v). Larvae were then immersed in propylene oxide and infil-
trated with 1:1 propylene oxide/araldite resin (Agar Scientific) over-
night and then in pure resin for 2 hours. After several changes of resin, 
samples were embedded and the resin was polymerized at 60°C for 
24 hours. After polymerization, 100-nm–thick sections were cut with 
an ultramicrotome and mounted on 300 mesh copper TEM grids. 
Thereafter, samples were poststained using uranyl acetate and TEM 
was performed with a JEOL 1200 EX electron microscope.
Measurement of TREK-1 current. Xenopus laevis was maintained and 
oocytes isolated under standard conditions according to established 
protocols. Capped cRNA transcripts were synthesized in vitro using 
the mMessage mMachine T7 transcription kit (Ambion). The cRNAs 
were purified and photometrically quantified. Human TREK-1c alone 
or together with human POPDC1 (WT or S201F mutant) was injected 
into Xenopus laevis oocytes at the indicated amounts of cRNA. Oocytes 
were incubated at 19°C for 24 to 48 hours in ND96 solution contain-
ing 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM 
HEPES (pH 7.4–7.5) supplemented with 50 mg/l gentamicin and 275 
mg/l sodium pyruvate. For experiments with elevated cAMP levels, 25 
mM theophylline or 1 mM 8-Br-cAMP (Tocris Bioscience) was supple-
mented to the storage solution, directly following the cRNA injection. 
Two-microelectrode voltage-clamp measurements were performed 
with a Turbo Tec-10 C amplifier (npi, Tamm). Data were recorded at a 
sampling rate of 2 kHz and lowpass filtered with 700 Hz. The oocytes 
were placed in a small-volume perfusion chamber and superfused 
with ND96 solution. Oocytes were held at –80 mV, and voltage was 
ramped from –120 to +45 mV within 3.5 seconds using a sweep time 
interval of 4 seconds. Since current amplitudes varied from 1 batch of 
oocytes to the next, currents were normalized to TREK-1c WT current 
amplitudes of the respective batch and recording day.
Patch-clamp experiments of HL-1 cells. HL-1 cells, provided by Wil-
liam C. Claycomb (Louisiana State University, Baton Rouge, Louisi-
ana, USA) (22), were transfected as described above. Action potentials 
were recorded in the whole-cell configuration under current clamp 
conditions at room temperature (22°C). For patch-clamp experi-
ments, HL-1 cells were superfused with solution containing 135 mM 
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